We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Faron Pharmaceuticals Oy | LSE:FARN | London | Ordinary Share | FI4000153309 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | |
---|---|---|---|---|---|
0.00 | 0.00% | 127.50 | 120.00 | 135.00 |
High Price | Low Price | Open Price | Shares Traded | Last Trade |
---|---|---|---|---|
127.50 | 127.50 | 127.50 | 195 | 08:00:19 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -28.73M | -0.4177 | -3.05 | 87.7M |
Date | Time | Source | Headline |
---|---|---|---|
16/4/2024 | 07:00 | UK RNS | Faron Pharmaceuticals Oy Faron confirms plans under new leadership |
15/4/2024 | 10:58 | ALNC | Faron Pharmaceuticals reappoints former finance chief on interim basis |
15/4/2024 | 07:00 | UK RNS | Faron Pharmaceuticals Oy Appointment of Chief Financial Officer |
08/4/2024 | 11:50 | ALNC | UPDATE: Faron Pharmaceuticals promotes COO to CEO as father retires |
08/4/2024 | 11:28 | ALNC | Faron Pharmaceuticals promotes COO to CEO as founder steps back |
08/4/2024 | 07:15 | ALNC | *Faron Pharmaceuticals says Markku Jalkanen to retire as CEO in Q2 but.. |
08/4/2024 | 07:10 | UK RNS | Faron Pharmaceuticals Oy Approval of Warrant Terms and Conditions |
08/4/2024 | 07:05 | UK RNS | Faron Pharmaceuticals Oy Decisions of the Board of Directors |
08/4/2024 | 07:00 | UK RNS | Faron Pharmaceuticals Oy Appointment of Chief Executive Officer |
05/4/2024 | 12:00 | UK RNS | Faron Pharmaceuticals Oy Results of the Annual General Meeting |
1 Year Faron Pharmaceuticals Oy Chart |
Intraday Faron Pharmaceuticals Oy Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions